A new design of the continual reassessment method

DOI10.1080/03610918.2019.1592191MaRDI QIDQ5082671zbMATH OpenOpenAlexFDO

Authors Weijia Zhang, Xikui Wang, Po Yang

Publication date 21 June 2022

Published in Communications in Statistics. Simulation and Computation (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1080/03610918.2019.1592191

zbMATH Keywords

continual reassessment methodmaximum tolerated doseBayesian methodphase I clinical trialtoxicity

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Recommendations

• Continual reassessment and related dose-finding designs
• A note on continual reassessment method
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Incorporating individual and collective ethics into phase I cancer trial designs
• Characterization of the likelihood continual reassessment method

Cites work

• A Random Walk Rule for Phase I Clinical Trials
• Adaptive clinical trial designs for phase I cancer studies
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials
• Biometric practicesimple benchmark for complex dose finding studies
• Consistency of continual reassessment method under model misspecification
• Continual Reassessment Method: A Likelihood Approach
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Continual reassessment designs with early termination
• Cumulative cohort design for dose-finding
• Design and Analysis of Phase I Clinical Trials
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• Estimating the Probability of Toxicity at the Recommended Dose Following a Phase I Clinical Trial in Cancer
• Group up-and-down designs for dose-finding
• Miscellanea. A stopping rule for the continual reassessment method
• Optimal Bayesian-feasible dose escalation for cancer phase I trials

Cited in

(10)

• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• A note on continual reassessment method
• Miscellanea. A stopping rule for the continual reassessment method
• A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in phase I clinical trials
• A novel doubling-tripling-threshold accepting hybrid algorithm for constructing asymmetric space-filling designs
• Incorporating individual and collective ethics into phase I cancer trial designs
• A continual reassessment method without undue risk of toxicity
• Characterization of the likelihood continual reassessment method
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Theoretical study of the continual reassessment method

This page was built for publication: A new design of the continual reassessment method

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5082671)